TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04054687
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
Study: NCT00151814
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
Study: NCT03047109
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
Study: NCT03047109
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
Study: NCT00017264
Drug: atrasentan hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02174835
Drug: AVP-786
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02174835
Drug: AVP-923
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01110746
Drug: LISPRO
Normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100IU/mL administered subcutaneously
Study: NCT03249285
Drug: Peri
Normalized name: Peri-DS
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
Study: NCT03249285
Drug: HCTZ
Normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
Study: NCT01214486
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
Study: NCT01451775
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: high dose of empagliflozin after overnight fasting for at least 10 h
Study: NCT01451775
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: low dose empagliflozin after overnight fasting for at least 10 h
Study: NCT01451775
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: high dose of empagliflozin after a standardised high fat breakfast
Study: NCT02932904
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine Overencapsulated Tablet
Study: NCT02932904
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine Overencapsulated Tablets.
Study: NCT01488097
Drug: sebelipase alfa
Normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study: NCT00699010
Drug: Oxycodone 5mg taken first
Normalized name: oxycodone 13.5 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: followed by Acurox 5/30mg with 48 hour washout
Study: NCT01263548
Drug: lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
Study: NCT00630968
Drug: Levetiracetam (Keppra)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03805022
Drug: Ifosfamide or dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
Study: NCT03805022
Drug: Ifosfamide or dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
Study: NCT00702117
Drug: flecainide
Normalized name: Flecainide
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg iv in 10 minutes
Study: NCT00702117
Drug: ajmaline
Normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg iv in 10 minutes
Study: NCT00702117
Drug: procainamide
Normalized name: Procainamide
DrugBank: Procainamide (DB01035)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg iv in 10 minutes
Study: NCT01966965
Drug: NEDAX
Normalized name: Nedocromil
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AS SPECIFIED AT THE LEAFLET
Study: NCT03786757
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Study: NCT03987893
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
Study: NCT00311896
Drug: Bemiparin
Normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03437785
Drug: CKD-495 75mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-495 75mg Tab.
Study: NCT03437785
Drug: CKD-495 150mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-495 150mg Tab.
Study: NCT03437785
Drug: Rebamipide 100mg
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 100mg Tab.
Study: NCT03437785
Drug: Placebo of the Rebamipide 100mg
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Placebo of the Rebamipide 100mg Tab
Study: NCT01212718
Drug: systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
Study: NCT03908944
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
Study: NCT03880903
Drug: normal saline and salbutamol
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
Study: NCT00793338
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20mg three times a day for 3 months.
Study: NCT01364428
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted.
Study: NCT01952756
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet (100 mg) twice per day for 12 weeks
Study: NCT03967392
Drug: Xylocaine
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TREATMENT
Study: NCT00716911
Drug: ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03042052
Drug: detrusor infection of Botulinum toxin
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: detrusor injection
Study: NCT01141881
Drug: Tissue Plasminogen Activator,bevacizumab ,follow up
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
Study: NCT03917420
Drug: Tenofovir 300Mg Oral Tablet
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily dose of the combo tab x 5 days pre-sampling
Study: NCT03917420
Drug: Emtricitabine 200 MG
Normalized name: emtricitabine 200 MG
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily dose of the combo tab x 5 days pre-sampling
Study: NCT02758392
Drug: JNJ-61178104 Intravenous
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.
Study: NCT02758392
Drug: JNJ-61178104 Subcutaneous
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-61178104 Subcutaneously on Day 1.
Study: NCT00801125
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02689258
Drug: Bupivicaine HCl
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl via injection
Study: NCT03373383
Drug: Padsevonil
Normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padsevonil in different dosages.
Study: NCT00500422
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
Study: NCT00500422
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
Study: NCT00500422
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
Study: NCT01250587
Drug: PDC31
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
Study: NCT03823248
Drug: Sanchi powder
Normalized name: Sanchi
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
Study: NCT03823248
Drug: MoLuoDan simulation
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
Study: NCT03823248
Drug: Sanchi powder simulation
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
Study: NCT03765645
Drug: Piperacillin + Tazobactam
Normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
Study: NCT02308644
Drug: intravitreal bevacizumab injection(1.25mg)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal bevacizumab injection(1.25mg) / Sham injection
Study: NCT00893516
Drug: CHOP
Normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00917436
Drug: Thiocolchicoside
Normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00168350
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03583424
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03583424
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03583424
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03583424
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03583424
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01899599
Drug: PankoMab-GEX
Normalized name: Immunoglobulin g1, anti-(mucin muc1) (human-mus musculus monoclonal pankomab-gex heavy chain), disulfide with human-mus musculus monoclonal pankomab-gex light chain, dimer
DrugBank: Gatipotuzumab (DB18861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01725191
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04372602
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: -For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
Study: NCT00736801
Drug: Salmeterol and Salmeterol / Fluticasone
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
Study: NCT01728025
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01279057
Drug: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
Study: NCT01589081
Drug: Intravenous Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
Study: NCT01589081
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
Study: NCT01356381
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Dosage 50mg b.i.d.
Study: NCT01845792
Drug: Cabazitaxel with Abiraterone Acetate
Normalized name: Cabazitaxel
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
Study: NCT01845792
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel intravenously every 3 weeks
Study: NCT00850395
Drug: maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
Study: NCT00233051
Drug: Salmeterol or Salmeterol/Fluticasone
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01425879
Drug: Akt Inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00193882
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg/m2 IV day 1
Study: NCT00193882
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800mg/m2/day IV days 1 - 4
Study: NCT00287742
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00386867
Drug: 800 mcg misoprostol via oral or buccal administration
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03426176
Drug: oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal administration of oxytocin (24 IU)
Study: NCT01209442
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
Study: NCT01209442
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
Study: NCT02098109
Drug: XM02 Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02098109
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02098109
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00496847
Drug: Beta TCP alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation of β-TCP (0.5 g) alone
Study: NCT01116232
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
Study: NCT01116232
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
Study: NCT01709695
Drug: Guanfacine Hydrochloride XR
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
Study: NCT03072485
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical sirolimus applied to the skin
Study: NCT03072485
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical metformin applied to the skin
Study: NCT03554291
Drug: Famotidine 20 MG
Normalized name: famotidine 20 MG
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 20 mg capsule taken daily for 24 weeks.
Study: NCT02251951
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)